Artemisinin-based combination therapy for ... - The Cochrane Library

Kayentao 2006 MLI (Continued)
Outcomes 1. ACPR at days 28, PCR adjusted and unadjusted
2. Mean haemoglobin at days 14 and 28
3. Gametocyte carriage during follow up
Not included in this review:
1. Proportion with fever days 0, 1, 2, 3
2. Proportion parasitaemic days 0, 1, 2, 3
Notes Country: Mali
Setting: Rural health centre
Transmission: Seasonal with peak in October
Resistance: CQ
Dates: Jul 2005 to Jan 2006
Funding: US Centers for Disease Control and Prevention, Malaria and Research Training
Center, University of Bamako
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Block randomisation (block size of 20)’.
No further details.
Allocation concealment? No None described
Blinding?
All outcomes
Incomplete outcome data addressed?
All outcomes
No Described as ’open-label’. Patients were not
informed of the drug received but no placebos
were used. Microscopists were unaware
of treatment allocation.
Yes Low losses to follow up in all groups (1.5%
AS+AQ vs 1.5% AS+SP vs 1.5% AQ+SP)
Free of selective reporting? Yes All WHO outcomes reported
Free of other bias? Yes No other sources of bias identified
Kobbe 2007 GHA
Methods Trial design: An open label randomized controlled trial
Follow up: Standardized history and examination, malaria film and haemoglobin on
days 0, 3, 7, 14, and 28 and any other day they felt unwell
Adverse event monitoring: ’The comparative tolerability was assessed by the risk of occurrence
of an adverse event’. For each adverse event causality was assessed as recommended
by the WHO.
Participants Number: 246 randomized
Inclusion criteria: Age 6 to 59 months, axillary temp > 37.5 ºC or history of fever in the
preceding 24 hrs, P. falciparum mono-infection 2000 to 200,000/µl, informed consent
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
70